Sugi Predict

Sugi Predict / Compounds / SCHEMBL473869

SCHEMBL473869

SCHEMBL473869

O=C(O)c1ccnc(Cl)c1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.63
▸ ASPH Q12797 1/20 0.63
▸ KDM8 Q8N371 1/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ NAPRT Q6XQN6 2/20 0.46
▸ KDM4C Q9H3R0 5/20 0.45
▸ KDM5A P29375 2/20 0.45
▸ KEAP1 Q14145 1/20 0.44
▸ NFE2L2 Q16236 1/20 0.44
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ KDM4A O75164 3/20 0.40
▸ KMO O15229 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ HIF1AN Q9NWT6 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418893 1.00 KDM4E (0.63) KDM4EASPHKDM8SMN1; SMN2LMNA
Nitrous Acid SCHEMBL28513459 0.93 KDM4E (0.61) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL1462341 0.84 KDM4E (0.44) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL27096669 0.82 KDM4E (0.43) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL23326783 0.82 KDM4E (0.43) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL29439594 0.80 SMN1; SMN2 (0.55) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL3667384 0.80 SMN1; SMN2 (0.55) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL83616 0.79 SMN1; SMN2 (0.59) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL29486104 0.79 SMN1; SMN2 (0.59) KDM4EASPHKDM8SMN1; SMN2LMNA
SCHEMBL3579780 0.79 KDM4E (0.68) KDM4EASPHKDM8SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116425672-A Preparation method of 2-chloro-3-fluoro-4- (trifluoromethyl) pyridine 江西科宁科技有限公司 2023-07-14 — — CN claimed
CN-101343366-A Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof UNIV SHANGHAI (CN) 2009-01-14 — — CN claimed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
CN-116829557-B Pentaheterocycle compound, preparation method and application thereof 上海艾力斯医药科技股份有限公司 2026-05-12 — — CN disclosed
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-07 — — US disclosed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 — — EP disclosed
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 — — US disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 — — US disclosed
EP-4709371-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2026-03-18 — — EP disclosed
EP-4655073-A2 CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO Arvinas Operations, Inc. (US) 2025-12-03 — — EP disclosed
WO-2025235740-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2025-11-13 — — WO disclosed
US-20080045511-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-02-21 — — US disclosed
US-7279580-B2 Imidazo-pyridine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LIMITED (GB) 2007-10-09 — — US disclosed
EP-1802579-A1 3-ARYLAMINO PYRIDINE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2007-07-04 — — EP disclosed
US-20070117798-A1 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. 2007-05-24 — — US disclosed
WO-2006045514-A1 3-ARYLAMINO PYRIDINE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2006-05-04 — — WO disclosed
EP-1511747-B1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2006-04-12 — — EP disclosed
US-20050165048-A1 Imidazo-pyridine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2005-07-28 — — US disclosed
EP-1511747-A1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2005-03-09 — — EP disclosed
WO-2003099816-A1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS ZC3HAV1, CCR1, CCR6 KDM4E 427/4885ASPH 4570/4885KDM8 660/4885
US-20080045511-A1 Non-nucleoside reverse transcriptase inhibitors ADORA2B, ADORA1, ADORA3 KDM4E 917/4885ASPH 646/4885KDM8 355/4885
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 KDM4E 306/4885ASPH 1893/4885KDM8 161/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS KDM4E 2825/4885ASPH 2227/4885KDM8 2685/4885
US-20050165048-A1 Imidazo-pyridine derivatives as ligands for gaba receptors GABRA3, GABRA2, GABRA5 KDM4E 2589/4885ASPH 2579/4885KDM8 2723/4885
US-20070117798-A1 Morpholine type cinnamide compound MLX, XDH, NOX4 KDM4E 2077/4885ASPH 3213/4885KDM8 2981/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS KDM4E 1792/4885ASPH 1318/4885KDM8 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.